Combined intravitreal ranibizumab and verteporfin photodynamic therapy versus ranibizumab alone for the treatment of age-related macular degeneration
Article Sidebar
Main Article Content
Abstract
Purpose
To compare same-day combined therapy of photodynamic therapy with verteporfin (PDT-V) and intravitreal ranibizumab versus monotherapy with ranibizumab for the treatment of choroidal neovascularization.
Methods
In this prospective study, the total number of eyes were randomized into two groups: in the first, treatment consisted of a combined therapy of PDT-V and ranibizumab 0.5 mg on the same day; in the second, ranibizumab 0.5 mg in 3 monthly injections. Best-corrected visual acuity (BCVA) and central macular thickness (CMT) on optical coherence tomography (OCT) were recorded before and 6 months after treatment.
Results
A total of 47 eyes of 47 subjects were enrolled in the study. In the combined-therapy group (group 1), the mean baseline BCVA ± standard deviation (SD) was 32.65 ± 11.09 letters (Snellen equivalent, 20/59); in the ranibizumab-alone group (group 2), 29.13 ± 9.03 letters (20/70). At 6 months’ follow-up, in group 1 the mean baseline BCVA was 39.06 ± 10.12 letters (20/42); in group 2, 33.87 ± 12.06 letters (20/57). Improvement was significant in both group 1 (P = 0.03) and group 2 (P = 0.002). In group 1, the mean CMT at baseline ± SD was 315 ± 95.49 μm; in group 2, 306.33 ± 71.61 μm. At 6 months’ follow-up, in group 1 it was 202 ± 52.02 μm; in group 2, 226 ± 65.58 μm. Reduction was significant in both group 1 (P = 0.0007) and group 2 (P = 0.00001). After 6-months, the rate of retreated eyes was 29.4% in group 1 and 43.3% in group 2. The need for retreatment did not depend on the treatment protocol (P = 0.34).
Conclusions
From a functional and anatomic point of view, the two treatments showed equivalent efficacy, with fewer retreatments in group 1. No serious adverse events, such as retinal detachment, endophthalmitis, or ocular hypertension occurred in either group.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Cook HL, Patel PJ, Tufai A. Age-related macular degeneration: diagnosis and management. British Medical Bulletin 2008;85:127-49.
Shah AR, Del Priore LV. Natural history of predominantly classic, minimally classic, and occult subgroups in exudative age-related macular degeneration. Ophthalmology 2009;116:1901-7.
Polito A, Isola M, Lanzetta P et al. The natural history of occult choroidal neovascularisation associated with age-related macular degeneration: a systematic review. Ann Acad Med Singapore 2006;35:145-50.
Bressler NM; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-TAP report 2. Arch Ophthalmol 2001;119:198-207.
Thys J, Dupont G, Rakic JM. VEGF inhibitors in ophthalmology Rev Med Liege 2009;64: 323-6.
Rosenfeld PJ, Brown DM, Heier JS et al. MARINA Study Group Ranibizumab for neovascular age-related macular degeneration N Engl J Med 2006;355:1419-31.
Kaiser PK. Verteporfin photodynamic therapy and anti-angiogenic drugs: potential for combination therapy in exudative age-related macular degeneration. Curr Med Res Opin 2007;23:477-87.
Antoszyk AN, Tuomi L, Chung CY, Singh A. FOCUS Study Group. Ranibizumab Combined With Verteporfin Photodynamic Therapy in Neovascular Age-related Macular Degeneration (FOCUS): Year 2 Results Am J Ophthalmol 2008;145:862-74.
Schmidt-Erfurth U & Wolf S. PROTECT Study Group. Same-day administration of verteporfin and ranibizumab 0.5 mg in patients with choroidal neovascularisation due to age-related macular degeneration. Br J Ophthalmol 2008;92:1628-35.
Kumar A, Gopalakrishnan K, Sinha S. Combination photodynamic therapy and intravitreal ranibizumab in neovascular AMD in a north Indian population: a pilot study. Retina 2008; 28:1132-7.
Wang W, Dean DC, Kaplan HJ.; Changes in visual function and thickness of macula after photodynamic therapy for age-related macular degeneration. Clin Ophthalmol 2010;3:483-8.
Do DV. Antiangiogenic approaches to age-related macular degeneration in the future. Ophthalmology 2009;116(10 Suppl):S24-6
Martin S Spitzer, Focke Ziemssen, Karl U. Treatment of age-related macular degeneration: focus on ranibizumab. Clinical Ophthalmology 2008;2:1-14.
Asensio-Sánchez VM. [Avastin is not the same as Lucentis, and Lucentis is not the same as Avastin] Arch Soc Esp Oftalmol 2009;84:427.
Kim IK, Husain D, Michaud N. Effect of intravitreal injection of ranibizumab in combination with verteporfin PDT on normal primate retina and choroid. Invest Ophthalmol Vis Sci 2006;47:357-63.
Schaal S, Kaplan HJ, Tezel TH. Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration? Ophthalmology 2008;115:2199-205. Epub 2008 Oct 18.
Ju M, Mailhos C, Bradley J. Simultaneous but not prior inhibition of VEGF165 enhances the efficacy of photodynamic therapy in multiple models of ocular neovascularization. Invest Ophthalmol Vis Sci 2008;49:662-70.
Patel S.Combination therapy for age-related macular degeneration. Retina 2009;29:S45–S48.
Ahn JK, Moon HJ. Changes in aqueous vascular endothelial growth factor and pigment epithelium-derived factor after ranibizumab alone or combined with verteporfin for exudative age-related macular degeneration. Am J Ophthalmol 2009;148:718-724.e1.
Debefve E, Pegaz B, Ballini JP. Combination therapy using verteporfin and ranibizumab: optimizing the timing in the CAM model. Photochem Photobiol 2009; 85:1400-8.